依非韦伦与利福平的相互作用：对HIV/TB患者依非韦伦剂量优化的治疗药物监测 - Suppr

Suppr

超能文献

Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients.

作者信息

Cabrera Salvador E, Cordero Miguel, Iglesias Alicia, Valverde María P, Domínguez-Gil Alfonso, García María J

出版信息

AIDS. 2008 Nov 30;22(18):2549-51. doi: 10.1097/QAD.0b013e3283189c07.

DOI:10.1097/QAD.0b013e3283189c07

PMID:19005282

Abstract

摘要

相似文献

Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients.依非韦伦与利福平的相互作用：对HIV/TB患者依非韦伦剂量优化的治疗药物监测

AIDS. 2008 Nov 30;22(18):2549-51. doi: 10.1097/QAD.0b013e3283189c07.

Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.在合并感染结核病/1型艾滋病病毒的患者中同时使用非核苷类逆转录酶抑制剂和利福平。

AIDS Res Hum Retroviruses. 2008 Jul;24(7):897-901. doi: 10.1089/aid.2007.0277.

CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.CYP2B6 基因型，但不是利福平为基础的抗结核联合治疗，解释了长期依非韦伦血浆暴露的变异性。

Pharmacogenomics. 2014 Aug;15(11):1423-35. doi: 10.2217/pgs.14.73.

Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.利福平及 CYP2B6 基因型对 HIV 合并结核病及非结核病患者长期依非韦伦自动诱导及其血药浓度的影响

Clin Pharmacol Ther. 2011 Sep;90(3):406-13. doi: 10.1038/clpt.2011.129. Epub 2011 Aug 3.

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.在撒哈拉以南非洲地区，接受基于利福平的抗结核治疗的同时，是否需要增加依非韦伦的剂量？HIV-TB药物基因组研究。

Pharmacogenomics. 2015;16(10):1047-64. doi: 10.2217/pgs.15.35. Epub 2015 Apr 1.

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.一项在接受利福平治疗的HIV感染患者中比较两种基于非核苷类逆转录酶抑制剂方案的血浆药物浓度和疗效的随机试验：N2R研究。

Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.接受利福平治疗的合并结核病的HIV感染患者中，每日600毫克依非韦伦与每日800毫克依非韦伦的比较：48周结果

AIDS. 2006 Jan 2;20(1):131-2. doi: 10.1097/01.aids.0000196181.18916.9b.

Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.在每日800毫克及含利福平的抗结核治疗方案的整个疗程中，依非韦伦谷浓度与病毒学失败无关。

J Antimicrob Chemother. 2006 Nov;58(5):1017-23. doi: 10.1093/jac/dkl357. Epub 2006 Sep 6.

Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma.同时测定人血浆中依非韦伦、利福平及其代谢物脱乙酰利福平的浓度。

J Pharm Biomed Anal. 2011 Dec 5;56(4):785-91. doi: 10.1016/j.jpba.2011.07.041. Epub 2011 Jul 30.

Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.在一名接受利福平治疗的患者中，将依非韦伦剂量减至每日一次200毫克。

AIDS. 2009 Mar 27;23(6):742-4. doi: 10.1097/QAD.0b013e32832914a3.

引用本文的文献

The pregnane X receptor in tuberculosis therapeutics.结核病治疗中的孕烷X受体

Expert Opin Drug Metab Toxicol. 2016;12(1):21-30. doi: 10.1517/17425255.2016.1121381. Epub 2015 Dec 5.

The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.结核治疗对 HIV 和结核双重感染患者中依非韦伦清除率的影响。

Eur J Clin Pharmacol. 2012 May;68(5):689-95. doi: 10.1007/s00228-011-1166-5. Epub 2011 Nov 23.

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.人群药代动力学/遗传药理学模型优化白种人 HIV 感染患者的依非韦伦治疗。

Antimicrob Agents Chemother. 2011 Nov;55(11):5314-24. doi: 10.1128/AAC.00194-11. Epub 2011 Sep 6.

Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.利福平对健康的非裔美国人和白种人志愿者中依非韦伦稳态血浆药代动力学的影响适度但有变化。

Antimicrob Agents Chemother. 2011 Jul;55(7):3527-33. doi: 10.1128/AAC.00980-10. Epub 2011 Apr 25.

Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.在一名 HIV 白种人患者中，将依非韦伦剂量减少至每日一次 200mg 的长期疗效和安全性。

Clin Drug Investig. 2010;30(6):405-11. doi: 10.1007/BF03256910.

Rifampin combination therapy for nonmycobacterial infections.利福平联合疗法治疗非分枝杆菌感染。

Clin Microbiol Rev. 2010 Jan;23(1):14-34. doi: 10.1128/CMR.00034-09.

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.在含利福平的结核病治疗期间调整非核苷类逆转录酶抑制剂的剂量：一种方法并不适用于所有人。

Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):55-68. doi: 10.1517/17425250903393752.

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.CYP2B6、CYP2A6 和 UGT2B7 基因多态性是 HIV 感染患者中依非韦伦中剂量浓度的预测因子。

AIDS. 2009 Oct 23;23(16):2101-6. doi: 10.1097/QAD.0b013e3283319908.

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.细胞色素P450 2B6基因型对人类免疫缺陷病毒患者中依非韦伦群体药代动力学的影响。

Antimicrob Agents Chemother. 2009 Jul;53(7):2791-8. doi: 10.1128/AAC.01537-08. Epub 2009 May 11.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验